Empagliflozin preserves mitochondrial function and reduces tubular injury in obese type 2 diabetic ZSF-1 rats

In obese ZSF-1 rats with type 2 diabetes, empagliflozin exerts nephroprotective effects by reducing tubular injury and preserving mitochondrial function through enhanced respiratory capacity, restored OXPHOS complex expression, and improved mitochondrial quality control, despite not improving glomerular filtration rate.

The Gist

The Big Picture: A "Power Plant" Crisis in the Kidney

Imagine your kidneys as a massive, high-tech water filtration factory. Its job is to clean your blood, remove waste, and keep your body balanced. Inside this factory, there are millions of tiny workers (cells) that do the heavy lifting. To keep working, these workers need a constant supply of energy, which comes from tiny power plants inside them called mitochondria.

In people with Type 2 diabetes and obesity, this factory gets overwhelmed. The "water" (blood sugar) is too thick and sticky, and the workers have to run on overdrive to filter it. Eventually, their power plants get clogged, damaged, and start producing toxic exhaust (oxidative stress). This causes the factory walls to crack and the workers to get injured. This is Diabetic Nephropathy (kidney disease).

The Experiment: Testing a New "Mechanic"

The researchers used a special breed of rats (ZSF-1) that naturally develop obesity, high blood pressure, and diabetes, just like humans. They wanted to see if a popular diabetes drug called Empagliflozin could act as a "mechanic" to fix the factory before it completely breaks down.

They split the rats into three groups:

1. The Healthy Group: Lean, normal rats.
2. The Sick Group: Obese, diabetic rats given a fake pill (placebo).
3. The Treated Group: Obese, diabetic rats given Empagliflozin.

What They Found: The Good, The Bad, and The Surprising

1. The "Flow Rate" Didn't Change (The Bad News)

Usually, when you fix a clogged pipe, the water flows faster. In kidney terms, this is called the GFR (Glomerular Filtration Rate).

• The Result: The sick rats had a slow flow rate. Surprisingly, the drug did not speed the flow back up to normal levels.
• The Analogy: Imagine a traffic jam on a highway. The drug didn't clear the traffic jam immediately; the cars were still moving slowly. However, just because traffic is slow doesn't mean the cars aren't getting safer or the drivers aren't less stressed.

2. The Factory Walls Got Repaired (The Good News)

Even though the flow rate didn't change, the drug did something amazing for the tubules (the pipes inside the factory).

• The Problem: In the sick rats, the pipes were getting clogged with "gunk" (protein casts) and the walls were getting damaged.
• The Fix: The drug cleared out the gunk and stopped the pipes from getting damaged. It was like sending a cleaning crew to scrub the pipes and patch the holes.
• Why it matters: The drug reduced the amount of protein leaking into the urine, which is a major sign of kidney damage.

3. The Power Plants Got a Tune-Up (The Science Magic)

This is the most important part of the study. The researchers looked inside the mitochondria (the power plants).

• The Problem: In the sick rats, the power plants were running on empty. They were missing key parts (proteins) needed to generate energy, and they were leaking energy instead of using it efficiently.
• The Fix: The drug acted like a tune-up kit.
  • It replaced the missing parts (restored protein expression).
  • It made the power plants burn fuel more efficiently.
  • It even increased the amount of "special oil" (cardiolipin) that keeps the machinery running smoothly.
• The Result: The workers in the kidney factory suddenly had better energy, less toxic exhaust, and could do their jobs without burning out.

4. The "Self-Cleaning" Mode

The drug also helped the cells manage their own trash.

• The Analogy: Think of autophagy as the factory's recycling bin. In the sick rats, the recycling bin was overflowing because the workers were too stressed to clean up. The drug helped the workers calm down and clean up their workspace more effectively, preventing a pile-up of cellular garbage.

The Conclusion: Why This Matters

The study shows that Empagliflozin works like a protective shield for the kidney's inner workings.

Even though it didn't immediately fix the "flow rate" (GFR), it saved the kidney cells from dying by:

1. Fixing the power plants (mitochondria) so they generate energy efficiently.
2. Cleaning the pipes (reducing tubular injury and casts).
3. Repairing the filters (improving podocyte health).

In simple terms: The drug didn't just treat the symptoms; it went into the engine room of the kidney, fixed the broken machinery, and stopped the factory from collapsing, even if the traffic outside (blood flow) was still a bit slow. This explains why the drug is so good at protecting kidneys in people with diabetes and obesity.

Technical Summary

1. Problem Statement

Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD). While Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors like empagliflozin have demonstrated significant renoprotective effects in clinical trials, the precise molecular mechanisms—particularly regarding mitochondrial function in the context of metabolic syndrome—remain under investigation.

• Context: The metabolic syndrome (obesity, hypertension, insulin resistance) accelerates kidney disease via oxidative stress and inflammation.
• Gap: While SGLT2 inhibitors are known to reduce glomerular hyperfiltration, their specific impact on tubular mitochondrial dysfunction, respiratory capacity, and mitochondrial quality control in an obese, hypertensive diabetic model needs further elucidation.
• Hypothesis: Empagliflozin exerts nephroprotection not just through hemodynamic changes, but by restoring mitochondrial function and reducing tubular injury in obese ZSF-1 rats.

2. Methodology

The study utilized a longitudinal experimental design using the ZSF-1 rat model, which spontaneously develops Type 2 Diabetes, obesity, hypertension, and progressive renal disease, closely mimicking human DN.

• Animal Groups:
  • Lean Controls: Healthy ZSF-1 rats.
  • Obese (Placebo): Obese ZSF-1 rats treated with vehicle.
  • Obese + Empa: Obese ZSF-1 rats treated with empagliflozin (30 mg/kg/day via chow) for 8 weeks, starting at 24 weeks of age.
• Key Assessments:
  • Physiological: Body weight, blood glucose, kidney mass (KW/Tibia ratio), and Glomerular Filtration Rate (GFR) measured via transdermal fluorescein-isothiocyanate conjugated sinistrin clearance.
  • Urinalysis: Total proteinuria, urinary $\alpha_1$-microglobulin (a marker of proximal tubular reabsorption), and glucose excretion.
  • Histology:
    • PAS Staining: Evaluated glomerular hypertrophy, tubular dilation, brush border loss, and protein cast formation (cortical and medullary).
    • Picrosirius Red: Assessed collagen I and III deposition (fibrosis).
    • Immunofluorescence: Evaluated podocyte health (Nephrin expression, WT1-positive cell count) and Collagen IV deposition.
  • Mitochondrial Function (Freshly Isolated Cortical Mitochondria):
    • High-Resolution Respiration: Measured oxygen consumption rates (OCR) using a Clark electrode with specific substrates to assess Complex I (Malate/Glutamate), Complex I+II (Succinate), and Complex IV (Ascorbate/TMPD).
    • Substrate Preference: Octanoylcarnitine (fatty acid oxidation) and Succinate.
    • Respiratory Control Ratio (RCR): Calculated as State 3 (ADP-stimulated) / State 2 (Leak).
  • Molecular Analysis:
    • Western Blot: Quantified protein expression of OXPHOS complexes (I–V), LC3-I/II (autophagy marker), Fis-1 (fission marker), and Porin (loading control).
    • Cardiolipin Assay: Measured cardiolipin content in mitochondrial membranes.
    • qPCR: Assessed SGLT1 and SGLT2 mRNA expression.

3. Key Contributions

• Mechanistic Insight: Provides direct evidence that empagliflozin improves mitochondrial respiratory capacity and restores the expression of OXPHOS complexes in the diabetic kidney, independent of GFR changes.
• Tubular Focus: Shifts the narrative from purely glomerular protection to significant tubular protection, demonstrating reduced tubular casts and improved reabsorptive function.
• Mitochondrial Quality Control: Links empagliflozin treatment to improved mitochondrial dynamics (reduced fission) and enhanced autophagic regulation, alongside increased cardiolipin content.
• Model Specificity: Offers a detailed characterization of the ZSF-1 rat model, highlighting that while GFR decline may be irreversible or hemodynamically complex in this specific model, structural and functional tubular improvements are achievable.

4. Key Results

Physiological & Renal Function:

• GFR: Obese rats showed a significant decline in GFR by 32 weeks compared to lean controls. Empagliflozin did not restore GFR, suggesting the treatment did not reverse the established hemodynamic decline in this model.
• Metabolic Control: Empagliflozin significantly reduced body weight gain and blood glucose levels. It induced pronounced glucosuria.
• Proteinuria: Total proteinuria was significantly elevated in obese rats but significantly reduced by empagliflozin.
• Tubular Markers: Urinary $\alpha_1$-microglobulin (indicating tubular dysfunction) was elevated in obese rats and normalized by empagliflozin treatment.

Histological Findings:

• Glomeruli: Obese rats exhibited glomerular hypertrophy and reduced nephrin expression (podocyte dysfunction), but no significant podocyte loss (WT1 count unchanged). Empagliflozin restored nephrin expression but did not reduce glomerular size.
• Tubules: Obese rats showed severe tubular injury (dilation, brush border loss, protein casts). Empagliflozin significantly reduced tubular damage and protein cast formation in both cortical and medullary regions.
• Fibrosis: Unexpectedly, empagliflozin increased Collagen I and III deposition compared to placebo obese rats, though it slowed Collagen IV thickening in the glomerular basement membrane.

Mitochondrial Function & Molecular Mechanisms:

• Respiration:
  • Complex I: Empagliflozin significantly increased ADP-stimulated (State 3) respiration and the Respiratory Control Ratio (RCR), indicating improved coupling efficiency.
  • Complex IV: Obese rats had significantly reduced Complex IV respiration; empagliflozin restored this function.
  • Fatty Acid Oxidation: Obese rats showed increased oxygen consumption with octanoylcarnitine (fatty acid substrate), which was normalized by empagliflozin.
• OXPHOS Protein Expression:
  • Obese rats had reduced expression of Complexes II, III, IV, and V.
  • Empagliflozin restored the expression of Complexes II, III, and IV to lean levels.
• Mitochondrial Integrity:
  • Cardiolipin: Empagliflozin significantly increased cardiolipin content, crucial for ETC stability.
  • Autophagy/Fission: Obese rats showed elevated LC3-I/II (autophagy activation) and Fis-1 (fission). Empagliflozin reduced these markers, suggesting a restoration of mitochondrial homeostasis and reduced stress-induced turnover.

5. Significance

This study demonstrates that the nephroprotective effects of empagliflozin in obese, hypertensive Type 2 diabetes are primarily mediated at the tubular level through the preservation and restoration of mitochondrial function.

• Decoupling GFR from Protection: The findings suggest that renoprotection can occur even without the stabilization of GFR, challenging the notion that GFR preservation is the sole metric of efficacy.
• Metabolic Reprogramming: The data supports the hypothesis that SGLT2 inhibitors induce a metabolic shift (likely toward ketone utilization and reduced fatty acid overload) that alleviates mitochondrial stress, reduces ROS production, and improves ATP generation efficiency.
• Clinical Implication: These results provide a mechanistic basis for the use of SGLT2 inhibitors in patients with metabolic syndrome and diabetic nephropathy, emphasizing their role in maintaining tubular integrity and mitochondrial health, which are critical for slowing disease progression even when hemodynamic parameters (GFR) are already compromised.